Shots:
- Neuraxpharm & mjn-neuro will launch Episeras for real-time early seizure detection in ambulatory & homecare settings, with EU rollout planned for the H2’26
- EPISERAS is being evaluated in the ongoing multicentre SERAS-Home_RWD study across Spain, the UK, & Germany, with interim data currently in preparation for publication
- Episeras is a non-invasive device that monitors brain activity via a discreet wearable earpiece & uses advanced AI to analyse electrical patterns, predicting & alerting pts & caregivers minutes before a seizure through a connected mobile app that displays real-time seizure-risk data for individuals with drug-resistant epilepsy
Ref: PRNewswire | Image: Neuraxpharm and mjn-neuro | Press Release
Related News: Neurona Therapeutics’ NRTX-1001 Secures the EMA’s Priority Medicines (PRIME) Designation for Drug-Resistant Focal Epilepsy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
